Aptevo Therapeutics (NASDAQ:APVO) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Aptevo Therapeutics (NASDAQ:APVO) from a hold rating to a sell rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Aptevo Therapeutics Trading Up 4.5%

NASDAQ APVO opened at $9.44 on Friday. Aptevo Therapeutics has a 1 year low of $7.66 and a 1 year high of $1,807.20. The company has a fifty day simple moving average of $18.03 and a 200 day simple moving average of $29.86. The company has a market cap of $8.87 million, a P/E ratio of -0.01 and a beta of 1.47.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($40.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($37.62) by ($2.52). Equities research analysts forecast that Aptevo Therapeutics will post -15.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.